To Do or Not to Do?-A Review of Cancer Surgery Triage Guidelines in COVID-19 Pandemic

Rajesh S Shinde, Mekhala D Naik, Shital R Shinde, Manish S Bhandare, Vikram A Chaudhari, Shailesh V Shrikhande, Anil K Dcruz, Rajesh S Shinde, Mekhala D Naik, Shital R Shinde, Manish S Bhandare, Vikram A Chaudhari, Shailesh V Shrikhande, Anil K Dcruz

Abstract

COVID-19 pandemic has emerged as a global health emergency involving more than 200 countries so far. The number of affected population is on rising, so is the mortality. This crisis has overwhelmed the healthcare infrastructures in many affected countries. Due to overall rising cancer incidence and specific concerns, a cohort of cancer patients forms a distinct subset of the population in whom a correct and timely treatment has a huge impact on the outcome. During this period, oncology care is definitely affected owing to many factors like lockdowns, reduced beds and deferral of elective cases to halt the spread of the pandemic. Surgery remains the best line of defence in many solid organ tumours especially in early stage and is potentially curative. China, the source of this pandemic, has taken more than 3 months to enter the post transitional phase of this pandemic. Deferring cancer surgeries for this long period may have a direct impact on the long-term outcomes of cancer patients. Many surgical oncology associations across the globe have come up with triage guidelines for surgical care of cancer patients; however, these are based on expert opinion rather than actual data. Herein, we intend to review these guidelines with respect to the risk of disease progression in cancer patients. In the absence of actual data on cancer surgery care during this pandemic, clinical decisions should be based on careful consideration of disease-related and patient-related factors. While some of the cancer surgeries can be safely delayed for some time, how long we can delay surgeries safely cannot be answered/ explained by any means. Thorough evaluation and discussion by an expert and experienced multidisciplinary team appears to be the most effective way forward.

Keywords: Cancer; Guidelines; Surgery; Triage.

Conflict of interest statement

Conflict of InterestNone

© Indian Association of Surgical Oncology 2020.

References

    1. Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–2019.
    1. World Health Organisation (2019) Managing epidemics: key facts about major deadly diseases.
    1. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–1179. doi: 10.1056/NEJMc2001737.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. Xie C, Jiang L, Huang G, Pu H, Gong B, Lin H, Ma S, Chen X, Long B, Si G, Yu H, Jiang L, Yang X, Shi Y, Yang Z. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis. 2020;93:264–267. doi: 10.1016/j.ijid.2020.02.050.
    1. Centers for Disease Control and Prevention Division of Viral Diseases. CDC 2019-novel coronavirus (2019-nCoV) Real-time RT-PCR diagnostic panel.
    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi: 10.1038/s41422-020-0282-0.
    1. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):16. doi: 10.1038/s41421-020-0156-0.
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
    1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337. doi: 10.1016/S1470-2045(20)30096-6.
    1. Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI (2020) A war on two fronts: cancer care in the time of COVID-19. Ann Intern Med. 10.7326/M20-1133
    1. Liu XM, Wang DQ. Consideration and suggestions on development of blood transfusion department under the epidemic situation of novel coronavirus pneumonia. Zhonghua Yi Xue Za Zhi. 2020;100(0):E013.
    1. Chang L, Yan Y, Wang L (2020) Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 10.1016/j.tmrv.2020.02.003
    1. Kristian S, Todd M, Alireza M. Considerations in the triage of urologic surgeries during the COVID-19 pandemic. Eur Urol
    1. Furukawa K, Irino T, Makuuchi R, Koseki Y, Nakamura K, Waki Y, Fujiya K, Omori H, Tanizawa Y, Bando E, Kawamura T, Terashima M. Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer. Gastric Cancer. 2019;22(4):864–872. doi: 10.1007/s10120-018-00910-y.
    1. Visser E, Leeftink AG, van Rossum PSN, Siesling S, van Hillegersberg R, Ruurda JP. Waiting time from diagnosis to treatment has no impact on survival in patients with esophageal cancer. Ann Surg Oncol. 2016;23(8):2679–2689. doi: 10.1245/s10434-016-5191-6.
    1. Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong YN, Patel SA, Boraas M, Chang EI, Topham NS, Egleston BL. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330–339. doi: 10.1001/jamaoncol.2015.4508.
    1. Shin DW, Cho J, Kim SY, Guallar E, Hwang SS, Cho BL, Oh JH, Jung KW, Seo HG, Park JH. Delay to curative surgery greater than 12 weeks is associated with increased mortality in patients with colorectal and breast cancer but not lung or thyroid cancer. Ann Surg Oncol. 2013;20(8):2468–2476. doi: 10.1245/s10434-013-2957-y.
    1. Fossati N, Rossi MS, Cucchiara V, et al. Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: can surgery be postponed safely? Urol Oncol. 2017;35(4):150.e9–150.e15. doi: 10.1016/j.urolonc.2016.11.010.
    1. Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ. Time to initial cancer treatment in the United States and association with survival over time: an observational study. PLoS One. 2019;14(3):e0213209. doi: 10.1371/journal.pone.0213209.
    1. Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Wang LS, Mehra R, Flieder DB, Ridge JA. Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States. J Clin Oncol. 2016;34(2):169–178. doi: 10.1200/JCO.2015.61.5906.
    1. Dolly D, Mihai A, Rimel BJ, Fogg L, Rotmensch J, Guirguis A, Yordan E, Dewdney S. A delay from diagnosis to treatment is associated with a decreased overall survival for patients with endometrial cancer. Front Oncol. 2016;6:31. doi: 10.3389/fonc.2016.00031.
    1. Jeon MJ, Kim WG, Kwon H, Kim M, Park S, Oh HS, Han M, Sung TY, Chung KW, Hong SJ, Kim TY, Shong YK, Kim WB. Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid micro carcinoma. Eur J Endocrinol. 2017;177(1):25–31. doi: 10.1530/EJE-17-0160.
    1. Froehner M, Heberling U, Zastrow S, Toma M, Wirth MP. Growth of a level III vena cava tumor thrombus within 1 month. Urology. 2016;90:e1–e2. doi: 10.1016/j.urology.2015.12.043.
    1. Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, Lotan Y, Capitanio U, Bensalah K, Marberger MJ, Shariat SF. A delay in radical nephroureterectomy can lead to upstaging. BJU Int. 2010;105(6):812–817. doi: 10.1111/j.1464-410X.2009.08821.x.
    1. Baudin E. Endocrine tumor board of Gustave Roussy. Adrenocortical carcinoma. Endocrinol Metab Clin N Am. 2015;44(2):411–434. doi: 10.1016/j.ecl.2015.03.001.
    1. Kabir T, Syn N, Ramkumar M, Yeo EYJ, Teo JY, Koh YX, Lee SY, Cheow PC, Chow PKH, Chung AYF, Ooi LL, Chan CY, Goh BKP. Effect of surgical delay on survival outcomes in patients undergoing curative resection for primary hepatocellular carcinoma: inverse probability of treatment weighting using propensity scores and propensity score adjustment. Surgery. 2020;167(2):417–424. doi: 10.1016/j.surg.2019.09.022.
    1. American College of Surgeons. COVID-19:Elective case triage guidelines for surgical care.
    1. Society of Surgical Oncology/COVID-19 resources/Disease site specific management resources.
    1. Indian Association of Surgical Oncology. Updated IASO COVID-19 guidelines.
    1. Association of Anaesthetists (2020) Anaesthetic management of patients during a COVID-19 outbreak.
    1. Ong S., Khee T. T. Practical considerations in the anaesthetic management of patients during a COVID ‐19 epidemic. Anaesthesia. 2020;75(6):823–824. doi: 10.1111/anae.15053.
    1. Sorbello M., El‐Boghdadly K., Di Giacinto I., Cataldo R., Esposito C., Falcetta S., Merli G., Cortese G., Corso R. M., Bressan F., Pintaudi S., Greif R., Donati A., Petrini F. The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice. Anaesthesia. 2020;75(6):724–732. doi: 10.1111/anae.15049.
    1. Cook T. M., El‐Boghdadly K., McGuire B., McNarry A. F., Patel A., Higgs A. Consensus guidelines for managing the airway in patients with COVID ‐19. Anaesthesia. 2020;75(6):785–799. doi: 10.1111/anae.15054.
    1. Dexter F, Parra MC, Brown J et al (2020) Perioperative COVID-19 defense: an evidence-based approach for optimization of infection control and operating room management. Anesth Analg. 10.1213/ANE.0000000000004829
    1. Lie SA, Wong SW, Wong LT, Wong TGL, Chong SY (2020) Practical considerations for performing regional anaesthesia: lessons learned from the COVID-19 pandemic. Can J Anaesth. 10.1007/s12630-020-01637-0
    1. Chan PKS, To KF. Lo AWI, et al. Persistent infection of SARS coronavirus in colonic cells in vitro. J Med Virol. 2004;74(1):1–7. doi: 10.1002/jmv.20138.
    1. Hu XH, Niu WB, Zhang JF, et al. Treatment strategies for colorectal cancer patients in tumor hospitals under the background of corona virus disease 2019. Zhonghua Wei Chang Wai Ke Za Zhi. 2020;23(3):201–208.
    1. Yu GY, Lou Z, Zhang W. Several suggestions of operation for colorectal cancer under the outbreak of corona virus disease 2019 in China. Zhonghua Wei Chang Wai Ke Za Zhi. 2020;23(3):208–211.
    1. Luo Y, Zhong M. Standardized diagnosis and treatment of colorectal cancer during the outbreak of corona virus disease 2019 in Renji hospital. Zhonghua Wei Chang Wai Ke Za Zhi. 2020;23(3):211–216.
    1. Chen YH, Peng JS. Treatment strategy for gastrointestinal tumor under the outbreak of novel coronavirus pneumonia in China. Zhonghua Wei Chang Wai Ke Za Zhi. 2020;23(2):I–IV.
    1. Tian Sufang, Hu Weidong, Niu Li, Liu Huan, Xu Haibo, Xiao Shu-Yuan. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. Journal of Thoracic Oncology. 2020;15(5):700–704. doi: 10.1016/j.jtho.2020.02.010.
    1. Li X, Liu M, Zhao Q, Liu R, Zhang H, Dong M, Xu S, Zhao H, Wei S, Song Z, Chen G, Chen J. Preliminary recommendations for lung surgery during 2019 novel coronavirus disease (COVID-19) epidemic period. Zhongguo Fei Ai Za Zhi. 2020;23(3):133–135.
    1. Xu Y, Liu H, Hu K, Wang M. Clinical management of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19) Zhongguo Fei Ai Za Zhi. 2020;23(3):136–141.
    1. Jiang ZF, Li JB. Ten hot issues on diagnosis and treatment of breast cancer under the outbreak of novel coronavirus pneumonia. Zhonghua Yi Xue Za Zhi. 2020;100(10):721–723.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit